Supporting Synovial Health in Equine OA Management

Arthramid 2.5% iPAAG targets the synovial membrane — a key driver of pain and inflammation associated with equine osteoarthritis.

Through synovial integration, Arthramid supports joint function while contributing to long-term clinical improvement supported by published research and real-world application.

Arthramid product in vet drawer

What is Arthramid?

Arthramid is a patented 2.5% injectable polyacrylamide hydrogel (iPAAG) used in the management of osteoarthritis in animals.

Following injection, Arthramid integrates into the synovial membrane to help support joint function and long-term synovial health.

Backed by more than 25 years of Contura research, Arthramid has been registered for veterinary use in New Zealand since 2020.

Ultrasound exam

Research-Backed Approach to Joint Health

  • 83.3% successful lameness resolution compared to 27.3% for triamcinolone treatment alone (JEVS 2021)
  • Synovial membrane integration confirmed within 14 days following intra-articular injection
  • No evidence of free gel or toxic effects observed during histological assessment
  • Supported by more than 25 years of Contura research across human and veterinary applications
Veterinary Support
Dr Leigh de Clifford

Synovium-Focused OA Management

with Dr Leigh de Clifford
Watch video

Interested in talking to us and learning more?

Send us a message and we will get in touch

BOOK NOW
Arthramid banner

Get The White Paper

This field is for validation purposes and should be left unchanged.

Secret Link